All patients were treated with lenvatinib every day and sintilimab intravenously once every 3 wk. Moreover, TACE was performed every 4-6 wk if there was obvious hepatic arterial blood supply to the HCC lesion according to contrast-enhanced abdominal magnetic resonance imaging or computed tomography combined with changes in tumour indicators such as alpha-fetoprotein. Patients received 12 mg of lenvatinib orally once a day for body weight ≥ 60 kg or 8 mg for body weight < 60 kg. Sintilimab (200 mg) was administered intravenously each time. Patients were administered TKIs and PD-1 antibodies within 3 d after the start of TACE.
Protocol detail
Combination Therapy for HCC Patients
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : Capital Medical University, Beijing Ditan Hospital
Top 5 similar protocols
Variable analysis
independent variables
- Treatment with lenvatinib every day
- Intravenous administration of sintilimab once every 3 weeks
- Transarterial chemoembolization (TACE) performed every 4-6 weeks if there was obvious hepatic arterial blood supply to the HCC lesion
- Tumor indicators such as alpha-fetoprotein
- Lenvatinib dose (12 mg for body weight ≥ 60 kg or 8 mg for body weight < 60 kg)
- Sintilimab dose (200 mg intravenously each time)
- Timing of TKIs and PD-1 antibodies administration (within 3 days after the start of TACE)
- No positive or negative controls were explicitly mentioned.
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!